PALO ALTO, Calif.--Incyte Pharmaceuticals won another LifeSeq subscriber last week and expanded its licensing arrangement with an existing subscriber. In a new deal, Bayer subscribed to the LifeSeq Gold database for therapeutic protein discovery, gaining access to Incyte’s portfolio of more than 50,000 genes. Incyte did not reveal terms of the deal, and said only that it could receive future milestone payments and royalties on product sales.
Meanwhile, Eli Lilly, which already subscribed to the LifeSeq Gold product, extened its agreement to become the first subscriber to Incyte’s database of single-nucleotide polymorphisms.
Separately, Incyte has hired John Vuko as its new CFO to replace Denise Gilbert who resigned last year. Vuko had previously been CFO at Achievement Radio Holdings and Ross Stores, and held various positions with the Cooper family of companies.